NCT02742727Unknown1 期
Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma
PersonGen BioTherapeutics (Suzhou) Co., Ltd.1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2016年3月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of CAR-pNK cell immunotherapy in patients with CD7 positive relapsed or refractory Leukemia and Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects with CD7+ malignancies in patients with no available curative treatment options who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
- •Eligible diseases: CD7 positive relapsed or refractory Leukemia and Lymphoma. ￚ Acute myeloid leukemia, previously identified as CD7+ ￚ Precursor T lymphoblast leukemia/lymphoma ￚ T-cell prolymphocytic leukemia ￚ T-cell large granular lymphocytic leukemia ￚ Peripheral T-cell lymphoma, NOS ￚ Angioimmunoblastic T-cell lymphoma ￚ Extranodal NK/T-cell lymphoma, nasal type ￚ Enteropathy-type intestinal T-cell lymphoma ￚ Hepatosplenic T-cell lymphoma
- •Patients 18 years of age or older, and must have a life expectancy > 12 weeks.
- •CD7 is expressed in malignancy tissues by immuno-histochemical (IHC) or Flow cytometry.
- •Assessable disease as measured by laboratory and bone marrow examinations.
- •Eastern cooperative oncology group (ECOG) performance status of 0-2 or karnofsky performance status (KPS) score is higher than
- •Females of child-bearing potential must have a negative pregnancy test and all subjects must agree to use an effective method of contraception for up to two weeks after the last infusion of CAR-pNK cells.
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements: serum creatinine ≤ 2.5mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5×upper limit of normal, serum total bilirubin ≤ 2.0mg/dL. These tests must be conducted within 7 days prior to registration.
- •Ability to give informed consent.
排除标准
- •Patients with symptomatic central nervous system (CNS) involvement.
- •Pregnant or nursing women may not participate.
- •Known HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •Serious illness or medical condition which would not permit the patient to be managed according to the protocol, including active uncontrolled infection, major cardiovascular, coagulation disorders, respiratory or immune system, myocardial infarction, cardiac arrhythmias, obstructive/restrictive pulmonary disease, or psychiatric or emotional disorders.
- •Concurrent use of systemic steroids. Recent or current use of inhaled steroids is not exclusionary.
- •Previously treatment with any gene therapy products.
- •The existence of unstable or active ulcers or gastrointestinal bleeding.
- •Patients with a history of organ transplantation or are waiting for organ transplantation.
- •Patients need anticoagulant therapy (such as warfarin or heparin).
- •Patients need long-term antiplatelet therapy (aspirin at a dose > 300mg/d; clopidogrel at a dose > 75mg/d).
结局指标
主要结局
Adverse events attributed to the administration of the anti-CD7 CAR-pNK cells
时间窗: 2 years
Determine the toxicity profile of the CD7 targeted CAR-pNK cells with Common Toxicity Criteria for Adverse Effects (CTCAE) version 4.0.
次要结局
- Clinical response to CD7 CAR-pNK cell infusions(Safety follow-up is 100 days from last CAR-pNK infusion)
- Determine the existence of CD7-CAR-pNK in vivo(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid TumorPancreatic CarcinomaTriple-Negative Invasive Breast CarcinomaMalignant Glioma of BrainColorectal CarcinomaGastric CarcinomaHepatocellular CarcinomaNon-small Cell Lung CancerNCT02839954PersonGen BioTherapeutics (Suzhou) Co., Ltd.10
Unknown
1 期
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell TumorsChronic Lymphocytic LeukemiaAcute Lymphoblastic LeukemiaB-cell LymphomaNCT04814004Kai Lin Xu; Jun Nian Zheng20
已完成
1 期
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung CarcinomaNon-small Cell Lung CancerNCT03656705Xinxiang medical university2
Unknown
1 期
Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MMMultiple MyelomaNCT03940833Asclepius Technology Company Group (Suzhou) Co., Ltd.20
Unknown
1 期
CAR-T Cell Immunotherapy in MUC1 Positive Solid TumorMalignant Glioma of BrainColorectal CarcinomaGastric CarcinomaNCT02617134PersonGen BioTherapeutics (Suzhou) Co., Ltd.20